In our last article, we discussed how “Healthy Aging” is emerging as a new, targeted therapeutic area. Among the most surprising candidates showing promise in this field are glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – medications originally developed to target diabetes. Research into GLP-1 RAs has an interesting history that started back in the early …
Continue reading “Could GLP-1 Receptor Agonists Become the First True “Longevity-Enhancing” Drugs?”
The life science industry has never moved faster, and the pace is only accelerating. Pipelines in oncology, rare disease, and cell and gene therapy are advancing with unprecedented velocity. Regulatory timelines are tightening, and the volume of new data is overwhelming traditional workflows. For medical communications agencies, this isn’t just about “keeping up.” It’s about …
Continue reading “Beyond Deadlines: The Growing Demands on MedComms”
A First-Hand Lesson in the Limits of Freelance Support A little while back, an agency partner brought us into a high-pressure situation. Their client, a major pharmaceutical company, was preparing for a product launch in Canada following regulatory approval. They needed a full suite of HCP-facing materials: several slide decks, marketing collateral, and talking points. …
Continue reading “Beyond Freelance: Why Medical Communications Needs Structure, Not Just Talent”
In our previous article, we reviewed the history of Patient Centered Care and how the Picker Principles provided a foundation for empowering patients and improving healthcare outcomes around the world. We highlighted that patient autonomy is a cornerstone of this approach, yet it is also one of the most challenging areas to effectively navigate. In …